IFNA1 and nonpapillary renal cell carcinoma: Although single-agent IFN-α therapy is meanwhile obsolete for metastatic ccRCC patients, this aspect deserves further investigation, since its combination with targeted agents like Bevacizumab is an established therapeutic option for first-line treatment [40].